<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hepatic resection for colorectal cancer liver metastasis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hepatic resection for colorectal cancer liver metastasis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hepatic resection for colorectal cancer liver metastasis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shimul A Shah, MD, MHCM
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sameer H Patel, MD, CMQ
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stanley W Ashley, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wenliang Chen, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 11, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H117807013">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 153,000 patients are newly diagnosed with colorectal cancer (CRC) in the United States annually [
         <a href="#rid1">
          1
         </a>
         ]. Among those who develop liver metastases, approximately 20 percent will be candidates for potentially curative liver resection. Long-term survival after surgery for colorectal liver metastases (CRLMs) has improved dramatically, with five-year overall survival (OS) rates doubling from approximately 30 percent in the 1980s to 1990s to almost 60 percent in the last two decades.
        </p>
        <p>
         An overview of how to manage potentially resectable CRLMs can be found here. (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy"
         </a>
         .)
        </p>
        <p>
         This topic will focus specifically on surgical aspects of liver resection for CRLMs and perioperative considerations. Other related topics include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatic resection techniques (see
         <a class="medical medical_review" href="/z/d/html/15094.html" rel="external">
          "Overview of hepatic resection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/88319.html" rel="external">
          "Open hepatic resection techniques"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Portal vein embolization (see
         <a class="medical medical_review" href="/z/d/html/106477.html" rel="external">
          "Preoperative portal vein embolization"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonsurgical locoregional therapies for CRLMs (eg, tumor ablation, hepatic intra-arterial chemotherapy, radiation) (see
         <a class="medical medical_review" href="/z/d/html/2515.html" rel="external">
          "Nonsurgical local treatment strategies for colorectal cancer liver metastases"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Integration of chemotherapy with resection for CRLMs (see
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Palliation of patients with stage IV CRC (see
         <a class="medical medical_review" href="/z/d/html/2495.html" rel="external">
          "Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4160085102">
         <span class="h1">
          PATIENT SELECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical resection of colorectal liver metastases (CRLMs) provides the greatest chance for cure and long-term survival and therefore is the treatment of choice for resectable CRLMs [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Appropriate patient selection is key to ensuring the best perioperative and long-term oncologic outcomes. Essential components in determining if a patient is a candidate for resection involve considering the following factors:
        </p>
        <p class="headingAnchor" id="H3699172757">
         <span class="h2">
          Patient factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Liver resection subjects patients to substantial physiologic stress. In patients with significant medical comorbidities (eg, significant underlying liver disease, extensive cardiopulmonary disease, advanced age), although a CRLM may be resectable, the perioperative risks may be prohibitive. Preoperative risk assessment is critical prior to surgery, as is allowing sufficient time for medical optimization. The details of risk assessment are discussed in other topics. (See
         <a class="medical medical_review" href="/z/d/html/1234.html" rel="external">
          "Assessing surgical risk in patients with liver disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6616.html" rel="external">
          "Evaluation of cardiac risk prior to noncardiac surgery"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6917.html" rel="external">
          "Evaluation of perioperative pulmonary risk"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4816.html" rel="external">
          "Preoperative medical evaluation of the healthy adult patient"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3933998624">
         <span class="h2">
          Tumor factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tumor biology is one of the most important factors that predict recurrence and survival. Prognostic tools based on clinicopathologic features have been developed to determine the risk of recurrence after resection, help guide whether surgery is an appropriate treatment, and determine if the patient might benefit from neoadjuvant chemotherapy [
         <a href="#rid3">
          3-6
         </a>
         ]. This is imperative in the modern era, in which patients typically receive chemotherapy before and/or after resection.
        </p>
        <p>
         Four separate clinical risk scores are currently in use to stratify patients based on their likelihood of recurrence  (
         <a class="graphic graphic_table graphicRef116620" href="/z/d/graphic/116620.html" rel="external">
          table 1
         </a>
         ). High-risk patients may be considered for initial chemotherapy in order to assess the biology of the tumor prior to resection (ie, patients who develop rapidly progressive metastases beyond the liver during this trial period will have been spared an unnecessary operation). In one study, in patients who did not receive initial chemotherapy prior to resection, all but the Konopke score correlated with the disease-free survival (DFS), but only the Nagashima score was predictive of overall survival (OS). Among patients who received chemotherapy followed by resection, all but the Konopke score were predictive of DFS and OS [
         <a href="#rid7">
          7
         </a>
         ]. Unfortunately, none of the scoring systems are able to predict disease-specific survival, particularly beyond five years. In clinical practice, these instruments are most often used to discuss outcomes and decision making when planning therapy with patients [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         The embryonic origin of the primary colon cancer also appears to affect the prognosis of patients who develop liver metastases. In a study of 727 patients who underwent chemotherapy followed by resection, CRLMs from midgut origin (ie, right colon tumors) were associated with worse pathologic response to chemotherapy and worse survival after resection compared with CRLMs from hindgut origin (ie, left/sigmoid colon tumors). This effect was independent of the
         <em>
          RAS
         </em>
         mutation status [
         <a href="#rid9">
          9
         </a>
         ]. The adverse impact of right- versus left-sided primary tumor location has been noted in other colorectal cancer (CRC) populations, including those with unresectable metastatic disease and localized nonmetastatic disease. (See
         <a class="medical medical_review" href="/z/d/html/2484.html" rel="external">
          "Pathology and prognostic determinants of colorectal cancer", section on 'Tumor location'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H679705865">
         <span class="h2">
          Anatomic factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         While previous guidelines for resection of CRLMs placed limits based on the number of lesions, tumor size, and margins, modern multidisciplinary consensus defines resectable CRC liver metastases simply as tumors that can be resected completely while leaving an adequate liver remnant  (
         <a class="graphic graphic_table graphicRef52622" href="/z/d/graphic/52622.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid10">
          10
         </a>
         ]. In other words, if resection can be accomplished to achieve an R0 resection and maintain a functional residual liver volume, other negative prognostic factors should not preclude surgery.
        </p>
        <p>
         We agree with guidelines developed from a consensus conference held by the American Hepato-Pancreato-Biliary Association, the Society for Surgery of the Alimentary Tract, and the Society of Surgical Oncology in 2006, which state [
         <a href="#rid11">
          11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients undergoing liver resection for hepatic colorectal metastases, a positive surgical margin is associated with a higher local recurrence and worse OS and should be avoided whenever possible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         While a wide (&gt;1 cm) resection margin should remain the goal when performing a liver resection, an anticipated margin of &lt;1 cm should not be used as an exclusion criterion for resection. (See
         <a class="local">
          'Wide versus narrow margin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment of resectability of hepatic colorectal metastases should focus on the ability to obtain a complete resection (negative margins).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The feasibility of hepatic resection should also be based on three criteria related to the remaining liver following resection: (1) the ability to preserve two contiguous hepatic segments, (2) preservation of adequate vascular inflow and outflow as well as biliary drainage, and (3) the ability to preserve adequate future liver remnant (&gt;20 percent in a healthy liver; &gt;30 percent after chemotherapy). (See
         <a class="medical medical_review" href="/z/d/html/15094.html" rel="external">
          "Overview of hepatic resection", section on 'Contraindications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of extrahepatic disease should no longer be considered an absolute contraindication to hepatic resection provided the patient is carefully selected and a complete (margin-negative) resection of both intra- and extrahepatic disease is feasible.
        </p>
        <p>
        </p>
        <p>
         Specific to the last point, portohepatic lymph node metastases associated with CRLMs are no longer considered an absolute contraindication to surgery [
         <a href="#rid12">
          12-16
         </a>
         ]. Outcomes are more favorable when nodal involvement is limited to the porta hepatis nodes, as opposed to the common hepatic artery or paraaortic nodes [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H389165632">
         <span class="h1">
          PREOPERATIVE EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H1606159391">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preoperative imaging is used to determine the number and extent of liver metastases as well as their anatomic distribution to aid in surgical planning. It should also be used to identify extrahepatic disease spread. Either high-quality contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) can be used. In our practice, we prefer MRI because it is most sensitive in detecting additional lesions that might preclude resection. However, availability and the expertise of both the radiologist and surgeon in interpreting the findings should dictate local practices. (See
         <a class="medical medical_review" href="/z/d/html/15094.html" rel="external">
          "Overview of hepatic resection", section on 'Preoperative imaging'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1564061550">
         <span class="h3">
          Computed tomography
         </span>
         <span class="headingEndMark">
          —
         </span>
         High-quality contrast-enhanced helical CT has a sensitivity between 70 to 95 percent and specificity of 96 percent for detecting liver metastases [
         <a href="#rid17">
          17-19
         </a>
         ]. CT is readily available at most centers with a relatively low cost. Despite the widespread use of CT, it is limited in the ability to identify lesions smaller than 1 cm and can have false negative rates as high as 10 percent. Furthermore, CT has low sensitivity in detecting extrahepatic metastases, such as those on serosal surfaces of both the liver and peritoneum and within the porta hepatis [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         CT can be used to estimate liver volume prior to resection. This is particularly important in patients undergoing portal vein embolization in order to increase the future liver remnant volume. (See
         <a class="medical medical_review" href="/z/d/html/106477.html" rel="external">
          "Preoperative portal vein embolization", section on 'Liver volumetry'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1600518092">
         <span class="h3">
          Magnetic resonance imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         MRI images have a better contrast-to-noise ratio than CT images, particularly in livers with high fat content. When used with contrast enhancement, MRI has a sensitivity and specificity of 81 and 97 percent, respectively, for detecting colorectal liver metastases (CRLMs) [
         <a href="#rid11">
          11,19,20
         </a>
         ]. Compared with CT, contrast-enhanced MRI is better at detecting subcentimeter lesions and CRLMs in patients with hepatic steatosis, a common occurrence after neoadjuvant chemotherapy [
         <a href="#rid21">
          21,22
         </a>
         ]. However, MRI is generally less accessible than CT and may be difficult to perform in patients with claustrophobia and metal implants [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2865079651">
         <span class="h3">
          Positron emission tomography
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of integrated positron emission tomography (PET)/CT in selecting optimal surgical candidates is uncertain. However, until additional data are available, including long-term follow-up of the Canadian trial [
         <a href="#rid24">
          24
         </a>
         ], we agree with the guidelines from the NCCN, which recommend a staging PET scan for patients who appear to have potentially surgically curable metastatic CRC.
        </p>
        <p>
         At least in theory, whole body PET scans have the potential to identify radiographically occult extrahepatic disease and optimize the selection of appropriate candidates for hepatic resection, mainly by reducing nontherapeutic laparotomy rates [
         <a href="#rid25">
          25-28
         </a>
         ]. However, the data supporting a benefit for PET in this setting are mixed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The benefit of adding PET to the staging strategy was subsequently shown in a randomized trial in which 150 patients with CRC liver metastases selected for hepatic resection by CT were randomly assigned to triple-phase contrast-enhanced CT imaging only or CT plus a separate PET scan [
         <a href="#rid28">
          28
         </a>
         ]. The primary outcome measure was the number of futile laparotomies (any laparotomy that did not result in complete tumor treatment or that did not result in a disease-free survival period of at least six months). The addition of PET significantly reduced the number of futile surgeries (28 versus 45 percent) and prevented unnecessary surgery in one of every six patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Two caveats must be considered when interpreting these results. First, this study used separate contrast-enhanced CT and PET images and not the increasingly popular integrated PET/CT imaging, in which both PET and CT are performed sequentially during a single visit on a hybrid PET/CT scanner. The CT component of integrated PET/CT imaging is performed in most institutions without the use of intravenous contrast material, which compromises the detection of small metastases both within and outside of the liver. At some institutions, PET/CT is carried out with intravenous contrast, but this practice is not widespread.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A benefit for integrated PET/CT could not be confirmed in a later randomized trial in which 404 patients with potentially resectable isolated CRC liver metastases (as established by contrast-enhanced CT of the chest, abdomen, and pelvis within 30 days of randomization) were randomly assigned to preoperative integrated PET/CT or no PET/CT [
         <a href="#rid24">
          24
         </a>
         ]. Of the 263 patients who underwent preoperative PET/CT, only 21 (8 percent) had a change in surgical management; these included seven (2.7 percent) who did not undergo laparotomy, four who had more extensive hepatic surgery, and nine (3.4 percent) who had additional organ surgery. Liver resection was performed in a similar proportion of both groups (91 versus 92 percent of the control group), and at a median follow-up of 36 months, survival did not differ between the groups (two-year survival 80 percent in both groups).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The superiority of PET over CT alone for detection of extrahepatic disease was also suggested in a systematic overview of retrospective data that utilized a scoring system to weigh the individual studies according to the quality of the data and the clinical impact of the radiographic findings [
         <a href="#rid26">
          26
         </a>
         ]. For the six articles judged to be of the highest quality [
         <a href="#rid29">
          29-34
         </a>
         ], the pooled sensitivity and specificity for PET were 80 and 92 percent, respectively, for hepatic disease, and 91 and 98 percent, respectively, for extrahepatic disease [
         <a href="#rid26">
          26
         </a>
         ]. The corresponding values for CT were 83 and 84 percent, respectively, for hepatic metastases, and 61 and 91 percent, respectively, for extrahepatic metastases. The percent change in clinical management from the performance of PET ranged from 20 to 32 percent (average 25 percent).
        </p>
        <p>
        </p>
        <p>
         The results of restaging PET scans (particularly if negative) must be interpreted in the context of recent therapy. Chemotherapy may reduce the sensitivity of PET for the detection of liver metastases, thought due to decreased cellular metabolic activity following chemotherapy [
         <a href="#rid35">
          35-37
         </a>
         ]. In one study, the false negative rate for hepatic metastases of a PET scan performed within four weeks of chemotherapy was 87 percent [
         <a href="#rid36">
          36
         </a>
         ]. Thus, surgical decisions should not be based on PET scan results in the liver.
        </p>
        <p>
         PET/CT scans are nearly always performed without intravenous contrast and therefore cannot substitute for contrast-enhanced CT scans.
        </p>
        <p class="headingAnchor" id="H430934775">
         <span class="h2">
          Diagnostic laparoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         With improved sensitivity of cross-sectional imaging modalities, diagnostic laparoscopy is no longer standard for evaluating patients with CRLMs. Instead, we only use it in patients with a suspicion of small-volume carcinomatosis on radiographic imaging studies (ie, CT, MRI, or PET) or who are at particularly high risk for harboring unresectable diseases (eg, a metachronous presentation with several liver metastases that do not respond to chemotherapy).
        </p>
        <p class="headingAnchor" id="H2417126249">
         <span class="h1">
          NEOADJUVANT CHEMOTHERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The availability of increasingly effective systemic chemotherapy for metastatic colorectal cancer (CRC) has prompted interest in preoperative or neoadjuvant systemic chemotherapy prior to liver resection.
        </p>
        <p>
         Initial systemic chemotherapy is often undertaken as a means of assessing the natural history of metastatic disease prior to embarking on metastasectomy, particularly in those with a synchronous presentation of metastatic disease. Patients whose disease progresses while on chemotherapy or who develop extrahepatic disease have biologically aggressive tumors that would not benefit from resection. (See
         <a class="local">
          'Synchronous colorectal liver metastases'
         </a>
         below.)
        </p>
        <p>
         Neoadjuvant systemic chemotherapy also has the potential to convert some patients with initially unresectable large or critically located liver metastases to resectable disease, although the true frequency with which this occurs is probably low. (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Patients with initially unresectable metastases'
         </a>
         .)
        </p>
        <p>
         The optimal selection criteria, specific regimen and duration of neoadjuvant chemotherapy, and the best way in which chemotherapy should be integrated with surgery in patients who present with synchronous metastatic disease have not been defined. Thus, the decision to proceed with or omit preoperative systemic chemotherapy should be made with multidisciplinary input, which is further discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H455837702">
         <span class="h2">
          Morphologic response
         </span>
         <span class="headingEndMark">
          —
         </span>
         After neoadjuvant therapy, standard criteria such as RECIST (Response Evaluation Criteria in Solid Tumors  (
         <a class="graphic graphic_table graphicRef74693" href="/z/d/graphic/74693.html" rel="external">
          table 3
         </a>
         )) are used to evaluate tumor response to cytotoxic agents; they may not be applicable to biologic agents such as
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , which have a cytostatic mechanism of action [
         <a href="#rid38">
          38-41
         </a>
         ]. Novel computed tomography (CT)-based morphologic criteria have been proposed that may more accurately predict pathologic response and prolonged survival in patients receiving preoperative chemotherapy, both with and without bevacizumab [
         <a href="#rid40">
          40,42
         </a>
         ]. However, these require external confirmation and validation.
        </p>
        <p class="headingAnchor" id="H2655315127">
         <span class="h2">
          Fiducial placement
         </span>
         <span class="headingEndMark">
          —
         </span>
         The introduction of modern chemotherapeutic agents has resulted in dramatic tumor responses for colorectal liver metastases (CRLMs), reaching almost 60 percent, some of which are complete. Disappearing liver metastases, which are no longer visible on cross-sectional imaging after neoadjuvant chemotherapy, can occur in 5 to 24 percent of patients [
         <a href="#rid43">
          43-46
         </a>
         ]. Lesions at the greatest risk of disappearing are those &lt;2 cm in diameter and &gt;1 cm deep in the liver parenchyma [
         <a href="#rid47">
          47
         </a>
         ]. Unfortunately, resection is still required because a true pathologic complete response or durable clinical response is rare (17 percent) after chemotherapy alone [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         To locate lesions at the time of resection, those at risk of disappearing after chemotherapy can be marked with a fiducial marker (eg, coil) before initiation of neoadjuvant chemotherapy [
         <a href="#rid48">
          48
         </a>
         ]. In a cohort of 32 patients with 41 CRLMs, 46 percent of lesions disappeared after neoadjuvant treatment. All such lesions in which a fiducial marker had been placed were successfully identified and either resected or ablated [
         <a href="#rid47">
          47
         </a>
         ]. Fiducial placement should be considered for all lesions &lt;2 cm in size, those that are located deeper than 1 cm in the liver parenchyma, and lesions outside of the proposed resection field [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2683924912">
         <span class="h2">
          Chemotherapy-related liver toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The advent of more effective systemic chemotherapies has increased the number of patients who are candidates for resection of CRLMs. However, chemotherapy-associated liver injury can result in impaired liver function and should be taken into account during operative planning. In general, a future liver remnant volume of &gt;30 percent is needed for livers that have undergone chemotherapy-associated changes.
        </p>
        <p>
         Longer durations of preoperative chemotherapy are associated with a greater potential for liver toxicity and postoperative complications. Many advocate limiting chemotherapy to four cycles (16 weeks) if a subsequent liver resection is planned. (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Post-treatment assessment and duration of neoadjuvant therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1432626663">
         <span class="h1">
          RESECTION OF COLORECTAL LIVER METASTASES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Liver metastases presenting at the same time with the primary colorectal cancer (CRC) or shortly thereafter are referred to as synchronous colorectal liver metastases (CRLMs). Metachronous CRLMs have a more delayed presentation, often after the primary CRC has been treated. There is no precise definition of synchronic versus metachronous disease; various studies have defined synchronous metastases as those occurring within 3, 6, or 12 months of the primary disease [
         <a href="#rid49">
          49
         </a>
         ]. The approach to resecting synchronous CRLMs is typically more complex than resecting metachronous CRLMs as the former often involve two lesions, the primary CRC and the CRLMs.
        </p>
        <p class="headingAnchor" id="H2824149500">
         <span class="h2">
          Metachronous colorectal liver metastases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Metachronous CRLMs typically develop after the primary CRC has been removed. Thus, surgical treatment of these lesions is not different from surgery for any other liver lesions (eg, hepatocellular carcinoma). Detailed descriptions of liver resection techniques can be found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/15094.html" rel="external">
          "Overview of hepatic resection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/88319.html" rel="external">
          "Open hepatic resection techniques"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1825236400">
         <span class="h3">
          Extensive bilobar metastases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although patients who have significant CRLMs in both lobes of the liver cannot be cured with a single operation, curative resection can still be performed in two stages [
         <a href="#rid50">
          50,51
         </a>
         ]. In the first stage, as many metastases are removed as possible. Systemic therapy is then administered to control the remaining disease while the patient recovers and the remnant liver hypertrophies. Portal vein embolization can be performed after the first operation to promote the extent of liver hypertrophy [
         <a href="#rid52">
          52
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/106477.html" rel="external">
          "Preoperative portal vein embolization"
         </a>
         ). If there is sufficient hypertrophy to prevent liver failure at four to six weeks, a second-stage operation is performed to remove the remaining CRLMs. Unfortunately, up to one-quarter of patients fail to undergo the second-stage operation due to disease progression [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4007691482">
         <span class="h2">
          Synchronous colorectal liver metastases
         </span>
         <span class="headingEndMark">
          —
         </span>
         The surgical approach to resecting synchronous CRLMs is more varied. Patients with both a primary CRC and CRLMs have the options of undergoing simultaneous resection of the primary tumor and CRLMs or a staged resection, which can be colorectal first (classic) or liver first (reverse approach). Systematic reviews and meta-analyses show no difference in outcomes regardless of which approach is taken [
         <a href="#rid54">
          54-56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2495.html" rel="external">
          "Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer", section on 'Management of the primary cancer'
         </a>
         .)
        </p>
        <p>
         In the METASYNC trial, 39 and 46 patients with initially resectable CRLMs were randomly assigned to simultaneous and delayed liver resection, respectively [
         <a href="#rid57">
          57
         </a>
         ]. While rates of intraoperative and postoperative complications were similar between the two groups, simultaneous resection resulted in superior two-year overall survival (87.2 versus 69.6 percent) and disease-free survival (35.9 versus 17.4 percent). However, there are several concerns about whether the two groups were perfectly matched: there were more patients with rectal primaries or &gt;3 liver metastases in the delayed resection group, adverse mutations that could influence survival were not tested or balanced, and the limited sample size did not allow for the complexity of either colorectal or liver surgery to be factored into the randomization process either.
        </p>
        <p>
         Thus, despite findings from the METASYNC trial, the decision to perform a staged or simultaneous resection should be individualized to each patient. At high-volume centers, patients with limited colorectal and extensive liver diseases or extensive colorectal and limited liver diseases can frequently be candidates for synchronous resections. Studies have shown that simultaneous resection even with major hepatectomies (&gt;3 segment resection) can be performed safely with this approach [
         <a href="#rid58">
          58
         </a>
         ]. However, patients requiring major colon and major hepatic surgery are best served by staged operations because of the greater risk of postoperative morbidity and compromises in the delivery of systemic treatment [
         <a href="#rid59">
          59
         </a>
         ]. The decision of which approach is used should be evaluated on a case-by-case basis and depends on surgeon expertise.
        </p>
        <p class="headingAnchor" id="H1549881577">
         <span class="h3">
          Selecting a surgical approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of the primary and metastatic lesions in patients with synchronous CRLM is often multidisciplinary and multimodal, involving chemotherapy, chemoradiation therapy, surgery, and locoregional therapy. The timing and sequence of surgical resection remain controversial but mostly depend on the acuity of symptoms and disease burden:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who present with symptoms from the primary CRC, such as bleeding, obstruction, or perforation, should undergo resection of the colorectal primary tumor first. Utilizing the liver-first approach can delay resection of the primary and increase the risk of developing complications related to the primary colorectal tumor. Studies have found rates of bleeding, obstruction, and perforation to be as high as 20 percent [
         <a href="#rid60">
          60,61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who are asymptomatic from the primary CRC may undergo a simultaneous or staged resection, depending on the extent of their liver involvement:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with a colorectal primary lesion in a favorable location (eg, right colon) and limited liver metastases may undergo simultaneous resection.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with extensive bilobar disease would benefit from the classic (colorectal-first) two-staged approach. Complete resection of such extensive CRLMs often requires an anatomic resection combined with multiple partial hepatectomies. This typically cannot be accomplished in a single operation, because of a high risk of liver failure. With the classic approach, at the time of colorectal primary resection, the CRLMs on the future liver remnant are resected with partial hepatectomies, leaving tumors behind on the portion of the liver that can be treated with a future anatomic resection. The patient then undergoes embolization of the portal vein on the side with the remaining tumors. After an adequate hypertrophy of the future liver remnant, a formal anatomic resection of the remaining diseases can be performed as the second-stage operation  (
         <a class="graphic graphic_figure graphicRef116621" href="/z/d/graphic/116621.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Some patients who are treated with neoadjuvant chemotherapy may benefit from a two-staged liver-first approach. In one example, patients with locally advanced rectal cancer (T4 and/or bulky tumor, or extensive nodal disease) may benefit from intensification of preoperative therapy using induction chemotherapy followed by chemoradiotherapy instead of chemoradiotherapy alone. If such patients have synchronous, potentially resectable liver metastases, they would be candidates for the reverse (liver-first) two-staged approach to resection: after four months of induction chemotherapy, hepatic resection typically takes place first; colorectal resection then follows in another two to four months upon completion of two additional months of chemotherapy and chemoradiotherapy to enhance local control (minimize the risk of a positive margin). Further delaying hepatic resection until a simultaneous resection can be carried out (at six to eight months) may worsen chemotherapy-induced liver changes and increase the risk of postoperative liver failure. (See
         <a class="medical medical_review" href="/z/d/html/2468.html" rel="external">
          "Neoadjuvant therapy for rectal adenocarcinoma", section on 'Total neoadjuvant therapy for locally advanced tumors'
         </a>
         and
         <a class="local">
          'Chemotherapy-related liver toxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4263387516">
         <span class="h3">
          Simultaneous resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         When simultaneous resection is performed, the liver resection is performed first. Intravenous fluids are minimized, and low central venous pressure is maintained until parenchymal transection is complete in order to minimize blood loss. Once the hepatic resection is completed, the patient can be hydrated and colorectal resection performed. After colorectal resection, the liver should be reexamined for bile leak and hemostasis. The details of liver parenchymal transection techniques can be found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/88319.html" rel="external">
          "Open hepatic resection techniques", section on 'Division of the liver tissue and hemostasis'
         </a>
         .)
        </p>
        <p>
         If the hepatic resection is more extensive than anticipated, or there is greater blood loss than anticipated, and/or the patient is not tolerating the procedure, the colorectal portion should be postponed and a staged approach utilized. This is critical because the remnant liver may not be able to withstand the stress of additional surgery and blood loss, resulting in acidosis and potential liver failure.
        </p>
        <p>
         Typical incisions used for simultaneous resection are midline laparotomy, a modified Makuuchi incision [
         <a href="#rid62">
          62
         </a>
         ], or an L-shaped incision, based on the location of the colorectal primary. Subcostal incisions can be used but may make access to portions of the colon and rectum challenging.
        </p>
        <p>
         Several studies have shown that length of stay and perioperative mortality are similar between simultaneous and staged CRLM resection, but patients who underwent simultaneous resection in these studies had higher numbers of right-sided colon primaries, smaller and fewer CRLMs, and less extensive liver resection [
         <a href="#rid63">
          63-66
         </a>
         ]. When a major hepatectomy was performed (resection of &gt;3 segments), simultaneous resection carried higher morbidity (36.1 versus 15.1 percent) and mortality (8.3 versus 1.4 percent) than staged resection [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
         The indications for a simultaneous resection have been discussed above. (See
         <a class="local">
          'Selecting a surgical approach'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3900535721">
         <span class="h3">
          Staged resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Traditionally, patients were treated with initial resection of the colorectal primary followed by administration of systemic chemotherapy and CRLM resection two to three months later as long as there was no disease progression [
         <a href="#rid67">
          67,68
         </a>
         ]. Advocates for the classic approach cite higher perioperative morbidity using the simultaneous approach. However, with advances in perioperative management and surgical technology, this viewpoint has been challenged [
         <a href="#rid11">
          11
         </a>
         ]. The contemporary approaches to staged resection can be either colorectal first (classic) or liver first (reverse).
        </p>
        <p class="headingAnchor" id="H1568543507">
         <span class="h4">
          Classic (colorectal-first) approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The classic colorectal-first approach involves resection of the colorectal primary tumor first, postoperative recovery, and two to three months of systemic chemotherapy. If the patient has stable disease or good response to chemotherapy, resection of the CRLMs is performed.
        </p>
        <p>
         As mentioned above, response to neoadjuvant chemotherapy is prognostic of improved overall survival (OS). A study examining patients with synchronous CRLMs who underwent staged, colorectal-first resection found that absence of progression after chemotherapy was associated with improved five-year OS (85 versus 35 percent) [
         <a href="#rid69">
          69
         </a>
         ]. The interval from resection of the primary tumor to CRLMs allows for identification of tumors with aggressive biology that will progress, and thereby excluding those patients from a second major operation with doubtful benefit [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
         The indications for a classic approach have been discussed above. (See
         <a class="local">
          'Selecting a surgical approach'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H502243272">
         <span class="h4">
          Reverse (liver-first) approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The liver-first or reverse approach has emerged as a viable option in the management of CRLMs. Proponents of this approach often cite that delaying resection of the colorectal primary to allow hepatic metastasectomy with or without systemic chemotherapy to be performed first rarely reduces resectability of the primary, while delaying resection of the hepatic metastases so that the colorectal primary can be resected first may result in progression of the liver metastases beyond resectability. Therefore, they argue liver resection should precede colorectal primary tumor resection [
         <a href="#rid71">
          71
         </a>
         ]. Furthermore, significant postoperative complications with a colorectal-first surgery can preclude both resection of the CRLM and systemic chemotherapy, which can also result in CRLM progression.
        </p>
        <p>
         The liver-first approach terminology is misleading as patients typically receive neoadjuvant therapy before surgery. The efficacy of this approach has been shown in the following studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A systematic review of the liver-first approach found that the overall morbidity and mortality after CRLM resection were 20 and 1 percent, respectively [
         <a href="#rid72">
          72
         </a>
         ]. Ultimately, 74 percent of patients had resection of their colorectal primary, and the rates of perioperative morbidity and mortality were 50 and 6 percent, respectively. The median overall survival was 40 months, and 52 percent of patients recurred. This analysis is limited in that only four studies were included, each with heterogeneous patient selection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a network meta-analysis comparing the classic, simultaneous, and liver-first surgical strategies, the authors found that five-year OS, 30 day mortality, and postoperative complications were comparable among all of the groups [
         <a href="#rid73">
          73
         </a>
         ]. However, there was a trend toward better outcomes with the liver-first approach and a nonsignificant increase in the rate of intra-abdominal collections/abscesses in the simultaneous group.
        </p>
        <p>
        </p>
        <p>
         The liver-first approach to a staged resection is often selected by surgeon preference. One sample scenario that calls for this approach has been discussed above. (See
         <a class="local">
          'Selecting a surgical approach'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3944469610">
         <span class="h1">
          SURGICAL TECHNIQUES
         </span>
         <span class="headingEndMark">
          —
         </span>
         This section will focus on operative considerations specific to resecting colorectal liver metastases (CRLMs). Detailed but generic descriptions of hepatic resection techniques can be found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/88319.html" rel="external">
          "Open hepatic resection techniques"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2609690523">
         <span class="h2">
          Parenchymal-sparing versus anatomic resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         CRLMs can be resected with an anatomic resection or a nonanatomic, parenchymal-sparing resection (PSR). Anatomic resections are based upon the segmental anatomy of the liver according to Couinaud  (
         <a class="graphic graphic_figure graphicRef81897" href="/z/d/graphic/81897.html" rel="external">
          figure 2
         </a>
         ), while the extent of a PSR is determined by the location and size of the CRLMs. (See
         <a class="medical medical_review" href="/z/d/html/15094.html" rel="external">
          "Overview of hepatic resection", section on 'Type and extent of resection'
         </a>
         .)
        </p>
        <p>
         The optimal extent of liver resection for CRLMs is subject to debate, but current trends are moving toward nonanatomic PSRs.
        </p>
        <p>
         The type of resection (anatomic versus PSR) has not been associated with significant differences in rates of positive margin, recurrence, or survival [
         <a href="#rid74">
          74
         </a>
         ]. A 2017 systematic review of PSR versus anatomic resection found that liver preservation did not compromise such oncologic outcomes [
         <a href="#rid75">
          75
         </a>
         ]. Furthermore, there were no differences in estimated blood loss, length of hospital stay, perioperative morbidity, incidence of R0 resection, and mortality. However, anatomic resection was associated with a higher rate of post-hepatic liver insufficiency (8 versus 2 percent). A 2019 systematic review associated PSR with shorter operative time, less blood loss, lower transfusion requirement, and fewer postoperative complications, while the overall survival and recurrence-free survival were not different between the PSR and non-PSR groups [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         PSR preserves greater hepatic reserve, particularly when chemotherapy-induced liver injury is a concern, and potentially increases salvageability in case of hepatic recurrence. In a retrospective study of solitary CRLMs &lt;3 cm, patients who underwent PSRs and anatomic resections had similar rates of liver recurrences (14 versus 17 percent), but those who underwent PSRs were more likely to undergo repeat hepatectomy when they did develop a recurrence in the liver remnant (68 versus 24 percent) [
         <a href="#rid77">
          77
         </a>
         ]. As a result, PSR was associated with a higher five-year overall survival (OS) than anatomic resection in a subgroup analysis of liver-only recurrences.
        </p>
        <p class="headingAnchor" id="H584571673">
         <span class="h2">
          Margins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obtaining a negative resection margin (R0) is one of the key tenets of oncologic surgery and, even in the era of modern chemotherapy, remains an important determinant of survival [
         <a href="#rid78">
          78
         </a>
         ]. For CRLMs, traditionally the standard resection margin is &gt;10 mm [
         <a href="#rid79">
          79,80
         </a>
         ]. However, that view has been challenged by several groups [
         <a href="#rid81">
          81,82
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15094.html" rel="external">
          "Overview of hepatic resection", section on 'Resection margins'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3848958578">
         <span class="h3">
          Wide versus narrow margin
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no prospective randomized clinical trials examining the impact of positive or close margin on survival for CRLMs, and such a study may never occur [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
         We suggest that resection margins of &gt;10 mm for CRLMs should be targeted when anatomically feasible. A 2017 meta-analysis of 34 cohort studies including 11,000 patients found that resection margins &gt;10 mm were associated with improved five-year overall survival compared with margins ≤10 mm (relative risk 0.91, 95% CI 0.85-0.97) [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         However, we also believe surgery should still be offered when such a wide margin is not feasible but, at minimum, a 1 mm resection margin can be achieved. Several large retrospective studies have examined margin status and found that a margin that is &lt;10 mm but negative is not associated with worse survival:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective study of 378 patients who underwent resection for CRLMs after neoadjuvant therapy at the MD Anderson Cancer Center, those with an R0 resection, defined as tumor-free margin ≥1 mm, had better five-year OS compared with those with a margin &lt;1 mm (55 versus 26 percent) [
         <a href="#rid78">
          78
         </a>
         ]. The impact of positive margin is most pronounced in patients with suboptimal response to systemic therapy. (See
         <a class="local">
          'Morphologic response'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a multicenter study of 551 patients undergoing liver resection for CRLMs, surgical margins were categorized as positive or negative with 1 to 4 mm, 5 to 9 mm, and &gt;10 mm of tumor-free margins [
         <a href="#rid81">
          81
         </a>
         ]. Although positive margins were associated with a greater risk of surgical margin recurrence, the width of negative margins did not affect survival, recurrence, or the site of recurrences.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 4915 patients who underwent resection for CRLM at the Memorial Sloan Kettering Cancer Institute, the median OS was 32, 40, 53, and 56 months for patients with 0 mm (R1), 0.1 to 0.9 mm, 1 to 9 mm, and &gt;10 mm margins, respectively [
         <a href="#rid85">
          85
         </a>
         ]. Compared with R1 resection, all margin widths, including submillimeter margins, correlated with prolonged OS, and there was no statistically significant difference in survival between the 1 to 9 mm and &gt;10 mm groups. These data suggest that wider margins should be attempted, but even a narrow margin should not preclude resection as long as it is negative.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 227 patients undergoing resection for CRLM after neoadjuvant therapy at Massachusetts General Hospital, positive margins (&lt;1 mm) significantly increased the risk of death without, but not with, post-liver-resection chemotherapy. Negative margin sizes of ≥1 to &lt;5 mm, ≥5 to &lt;10 mm, and ≥10 mm were not a significant predictor of OS [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 633 patients who underwent surgery for CRLMs, having a &gt;1 mm margin was associated with an improved OS of 65 versus 36 months in those with a &lt;1 mm margin [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         At a molecular level, pathologic examination and deoxyribonucleic acid (DNA) analysis of normal liver tissue surrounding resected CRLMs revealed that almost all micrometastases and viable cancer cells were found within 4 mm of the tumor border [
         <a href="#rid88">
          88,89
         </a>
         ]. This was true even in patients who had reduction in tumor size secondary to neoadjuvant therapy [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H509107159">
         <span class="h3">
          RAS mutational status
         </span>
         <span class="headingEndMark">
          —
         </span>
         Signaling through the
         <em>
          RAS
         </em>
         oncogene is an important regulator of cellular signal transduction, and mutations in
         <em>
          RAS
         </em>
         represent an early step in colorectal tumorigenesis. In addition,
         <em>
          RAS
         </em>
         mutations portend a more aggressive tumor biology of CRLMs and have been associated with more positive margins and worse survival after resection. Consequently, anatomic resection and/or a wider surgical margin (eg, &gt;10 mm) may be indicated for patients with
         <em>
          RAS
         </em>
         -mutated CRLMs.
        </p>
        <p>
         In a retrospective study of 633 patients who underwent curative-intent resection for CRLM at the MD Anderson Cancer Center, 36.2 percent had a
         <em>
          RAS
         </em>
         mutation [
         <a href="#rid90">
          90
         </a>
         ]. Patients with a
         <em>
          RAS
         </em>
         mutated tumor were twice as likely to have a positive resection margin (&lt;1 mm) compared with those without a
         <em>
          RAS
         </em>
         mutation (11 versus 5 percent).
         <em>
          RAS
         </em>
         mutation (hazard ratio 1.6) and positive margin (hazard ratio 3.4) were independent predictors of poor overall survival by multivariate analysis. The authors proposed aiming for a 1 cm resection margin for
         <em>
          RAS
         </em>
         -mutated CRLMs.
        </p>
        <p>
         Others reported that even a wider resection margin may not be sufficient to overcome the aggressive tumor biology associated with a
         <em>
          RAS
         </em>
         mutation. In study of 411 patients who underwent resection for CRLMs at Johns Hopkins, a 1 to 4 mm margin was associated with improved survival compared with a positive margin (&lt;1 mm or R1) for wild-type
         <em>
          KRAS
         </em>
         tumors, with which a wider resection margin did not further improve survival. In
         <em>
          KRAS
         </em>
         -mutated tumors, however, negative margin status, which included a 1 cm margin, did not improve survival [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
         Consequently, other investigators studied whether anatomical resections would benefit
         <em>
          RAS
         </em>
         -mutated CRLMs [
         <a href="#rid92">
          92
         </a>
         ]. In one such study, 389 patients underwent either an anatomic or nonanatomic CRLM resection. Patients with wild-type
         <em>
          RAS
         </em>
         tumors had no difference in disease-free survival (DFS) based on the type of resection. By contrast, patients with
         <em>
          RAS
         </em>
         mutations had worse DFS with nonanatomic compared with anatomic resection (10.5 versus 33.8 months). The authors of the study suggested that the more aggressive anatomic resections may be warranted in patients with
         <em>
          RAS
         </em>
         -mutated tumors.
        </p>
        <p>
         The prognostic influence of
         <em>
          RAS
         </em>
         and other mutations is also discussed below. (See
         <a class="local">
          'Oncologic'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2647232504">
         <span class="h3">
          Intraoperative reresection to obtain negative margins
         </span>
         <span class="headingEndMark">
          —
         </span>
         The impact of intraoperative reresection to obtain negative margins has been examined. Data suggest that additional margin &gt;1 cm obtained by intraoperative reresection does not confer the same survival benefit as an initial negative margin of &gt;1 cm [
         <a href="#rid93">
          93
         </a>
         ] and that a negative margin achieved at reresection was not associated with better survival or fewer recurrences compared with R1 resections. This is probably because a narrow or positive margin is reflective of aggressive tumor biology, which is a more important prognostic factor than surgical techniques [
         <a href="#rid94">
          94
         </a>
         ]. Despite that, every effort should be made during resection to obtain an initially negative margin.
        </p>
        <p class="headingAnchor" id="H2519649444">
         <span class="h2">
          Air cholangiogram
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postoperative bile leak is a major complication that occurs after liver resection in approximately 1 in 10 patients. We routinely perform an air cholangiogram to minimize it.
        </p>
        <p>
         After liver parenchymal transection and hemostasis, a catheter is inserted into the cystic duct stump (assuming cholecystectomy has been performed) and secured with a silk suture [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
         In the first portion of the air cholangiogram test, liver ultrasonography is performed while air is injected into the catheter and digital pressure is applied to occlude the distal common bile duct. Pneumobilia visible on ultrasound indicates patency of the duct. Absence of pneumobilia could be due to bile duct obstruction, massive air leak via a large open bile duct, or, most commonly, incomplete manual occlusion of the distal common bile duct (with air escaping into the duodenum).
        </p>
        <p>
         In the second portion, the right upper quadrant is filled with sterile water or
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         to submerge the liver. Air is again injected via the cholangiogram catheter. The presence of bubbles indicates air leaking through one or more open bile ducts. Each open duct that is identified can be suture ligated, and the procedure is repeated until no more leaks are identified. In one study using this method, 62 percent of the bile duct leaks were identified, which reduced the bile leak rate to 1.9 percent [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H874591887">
         <span class="h2">
          Drains
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine placement of intra-abdominal drains after hepatectomy has no clear benefit [
         <a href="#rid96">
          96,97
         </a>
         ]. Thus, we do not routinely use drains in our practice.
        </p>
        <p>
         In a large multi-institutional study of 1041 patients who underwent a major hepatectomy (&gt;3 segments) without a biliary anastomosis, approximately one-half had drains placed intraoperatively at the surgeon's discretion. Primary drain placement was associated with increased risk of bile leak and 30 day readmission rate but no reduction in the need for secondary drainage procedures [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H654952595">
         <span class="h2">
          Open versus minimally invasive resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatic resection for colorectal cancer liver metastasis can be performed open or minimally invasively. Since 2015, the number and complexity of minimally invasive liver resections have both increased dramatically. In experienced centers, an estimated 60 to 70 percent of patients with CRLMs are candidates for minimally invasive resection [
         <a href="#rid99">
          99
         </a>
         ]. Minimally invasive resection, in carefully selected patients, has been shown to have superior short-term outcomes and superior or at least comparable long-term (oncologic) outcomes to its open counterpart [
         <a href="#rid100">
          100
         </a>
         ]. The techniques and outcomes of minimally invasive liver surgery are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/109268.html" rel="external">
          "Minimally invasive liver resection (MILR)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3725694322">
         <span class="h1">
          UNRESECTABLE COLORECTAL LIVER METASTASES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 80 percent of patients with metastatic colorectal cancer (CRC) are not candidates for resection at diagnosis [
         <a href="#rid101">
          101
         </a>
         ]. Initial treatment options include chemotherapy and/or locoregional therapies such as ablation.
        </p>
        <p>
         The term "conversion therapy" has been proposed to designate the use of induction chemotherapy in such patients [
         <a href="#rid102">
          102
         </a>
         ]. It is reported that between 12 and 33 percent of patients with "initially unresectable" hepatic metastases have a sufficient objective response to conversion therapy to permit a subsequent complete (R0) resection  (
         <a class="graphic graphic_table graphicRef62458" href="/z/d/graphic/62458.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid103">
          103-110
         </a>
         ].
        </p>
        <p>
         Ablation is a parenchymal-sparing strategy that is increasingly used for management of small or unresectable tumors. (See
         <a class="medical medical_review" href="/z/d/html/2515.html" rel="external">
          "Nonsurgical local treatment strategies for colorectal cancer liver metastases"
         </a>
         .)
        </p>
        <p>
         For patients with borderline resectable disease or inadequate future liver remnant for resection, a combined ablation/resection approach can be used for colorectal liver metastasis (CRLM) treatment:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a multicenter study of 288 patients who underwent combined intraoperative ablation and resection of CRLMs, the five-year overall survival was 37 percent, and local recurrence-free survival from ablated lesions was 78 percent. Postoperative mortality was 1 percent, and the overall complication rate was 35 percent [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another study compared combined ablation and resection with two-stage hepatectomy for bilobar CRLMs. The combined ablation/resection strategy achieved a better median overall survival (46 versus 36 months) and cost savings of &gt;$25,000 [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Management of initially unresectable CRLMs and locoregional therapies for categorically unresectable CRLMs are further discussed in other topics. (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2515.html" rel="external">
          "Nonsurgical local treatment strategies for colorectal cancer liver metastases"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1778452396">
         <span class="h1">
          REPEAT RESECTION FOR COLORECTAL LIVER METASTASES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrences following initial resection of colorectal liver metastases (CRLMs) can occur in up to 57 percent of patients, with the liver being the most common location of recurrences [
         <a href="#rid113">
          113
         </a>
         ]. Reresection for recurrence of CRLM is a safe and feasible option in properly selected patients. Sufficient future liver reserve is paramount in order to prevent post-hepatectomy liver failure.
        </p>
        <p>
         Although randomized trials have not been conducted to prove benefit, repeat hepatic resection may be considered in selected patients who recur in the liver with no evidence of extrahepatic disease and a good performance status. In several reported series, perioperative mortality rates were less than 5 percent, and overall survival rates ranged from 20 to 43 percent at two to five years  (
         <a class="graphic graphic_table graphicRef67710" href="/z/d/graphic/67710.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid14">
          14,114-128
         </a>
         ].
        </p>
        <p>
         Patients with a relapse-free interval of longer than one year appear to have a more favorable outcome from reresection. Other factors associated with a poor outcome include synchronous resection for the first liver metastases and the presence of multiple lesions at second hepatectomy [
         <a href="#rid116">
          116-118,122,129
         </a>
         ].
        </p>
        <p>
         Interestingly, recurrences at the margin are uncommon [
         <a href="#rid81">
          81,130,131
         </a>
         ]. Repeat hepatectomy is a safe and feasible option, with studies reporting five-year overall survival rates after reresection of 33 to 73 percent with no perioperative mortality [
         <a href="#rid116">
          116,132,133
         </a>
         ]. Evaluation of prognostic factors has identified an initial largest CRLM &gt;5 cm and positive margins at initial resection to be associated with worse survival [
         <a href="#rid132">
          132
         </a>
         ].
         <strong>
         </strong>
        </p>
        <p class="headingAnchor" id="H3192014590">
         <span class="h2">
          Recurrence after two-stage hepatectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disease is thought to recur more frequently after two-stage hepatectomies than after single-stage liver resections because of a more extensive tumor load. (See
         <a class="local">
          'Extensive bilobar metastases'
         </a>
         above.)
        </p>
        <p>
         Nevertheless, long-term survival is still possible with repeat surgery for recurrence even in this cohort of patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In 81 patients who completed two-stage liver resection for extensive CRLM, 62 (77 percent) had recurrence [
         <a href="#rid134">
          134
         </a>
         ]. Repeat surgery was performed in 38 patients, of which 31 were potentially curative. For these 31 patients, the disease-free survival rates at one, three, and five years were 33.0, 14.1, and 12.1 percent after the repeat surgery and 54.7, 30.8, and 22.5 percent after the initial two-stage hepatectomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another 111 patients who completed two-stage hepatectomy for CRLM, 83 (75 percent) developed recurrence [
         <a href="#rid135">
          135
         </a>
         ]. Thirty-one patients (37 percent) underwent resection for recurrence, and 11 (13 percent) underwent multiple resections for recurrence. The median overall survival among patients with recurrence was much longer with than without resection (143 versus 49 months).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2391599364">
         <span class="h1">
          POSTOPERATIVE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postoperative care following liver resection is described in another topic. (See
         <a class="medical medical_review" href="/z/d/html/15094.html" rel="external">
          "Overview of hepatic resection", section on 'Postoperative care'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3062272079">
         <span class="h1">
          OUTCOMES
         </span>
        </p>
        <p class="headingAnchor" id="H1988811045">
         <span class="h2">
          Perioperative
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the modern era, perioperative mortality associated with colorectal liver metastasis (CRLM) resection is &lt;5 percent, and around 1 percent in high-volume centers, regardless of whether a simultaneous, classic, or reverse approach is used. (See
         <a class="local">
          'Selecting a surgical approach'
         </a>
         above.)
        </p>
        <p>
         Individual retrospective studies for simultaneous resection reported varying rates of perioperative morbidity ranging from 5 to 48 percent for minor hepatectomy to 33 to 55 percent for major hepatectomy. With staged procedures, morbidity rates ranged from 16 to 67 percent [
         <a href="#rid136">
          136
         </a>
         ].
        </p>
        <p>
         A systematic review and meta-analysis of 41 studies (over 12,000 patients) undergoing resection of CRLM associated the occurrence of postoperative complication with reduced overall survival (hazard ratio 1.43, 95% CI 1.3-1.57) and reduced disease-free survival (hazard ratio 1.38, 95% CI 1.27-1.49) [
         <a href="#rid137">
          137
         </a>
         ].
        </p>
        <p>
         Postoperative complications of liver resection, which include bile leak, ascites, liver failure, and pulmonary and thrombotic complications, are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/15094.html" rel="external">
          "Overview of hepatic resection", section on 'Complications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3676356069">
         <span class="h2">
          Oncologic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Five-year overall survival (OS) rates for patients with CRLMs receiving systemic chemotherapy alone, even with modern agents, are less than 11 percent, with only 2 percent having a durable response [
         <a href="#rid138">
          138
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'Systemic therapy versus supportive care'
         </a>
         .)
        </p>
        <p>
         Resection for CRLMs is possible in approximately 25 percent of patients with liver-only disease. However, in the subset of patients who undergo liver surgery, five-year OS rates have improved from 30 to nearly 60 percent [
         <a href="#rid139">
          139-141
         </a>
         ]. In studies with long-term follow-up, 10 year OS rates of up to 24 percent have been reported, and there are even reports of &gt;20 year survivors [
         <a href="#rid3">
          3,142
         </a>
         ].
        </p>
        <p>
         Resection offers the greatest likelihood of cure for patients with liver-isolated colorectal cancer (CRC). In surgical case series, five-year survival rates after resection range from 24 to 58 percent, averaging 40 percent  (
         <a class="graphic graphic_table graphicRef74509" href="/z/d/graphic/74509.html" rel="external">
          table 6
         </a>
         ), and surgical mortality rates are generally &lt;5 percent [
         <a href="#rid3">
          3,4,25,114,139,140,143-151
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1547095923">
         <span class="h3">
          RAS mutation
         </span>
         <span class="headingEndMark">
          —
         </span>
         As discussed above, signaling through the
         <em>
          RAS
         </em>
         oncogene is an important regulator of cellular signal transduction, and mutations in
         <em>
          RAS
         </em>
         represent an early step in colorectal tumorigenesis. Consequently,
         <em>
          RAS
         </em>
         mutations are associated with poor prognosis; patients with
         <em>
          RAS
         </em>
         -mutated tumors have higher levels of recurrence and poorer OS after resection of CRLMs and a greater chance of positive margins. The influence of
         <em>
          RAS
         </em>
         mutations on the width of the surgical margin in patients undergoing metastasectomy is addressed above. (See
         <a class="local">
          'Margins'
         </a>
         above.)
        </p>
        <p>
         As an example, in a retrospective study of 421 patients who underwent hepatic resection for CRLM, 44 percent had a
         <em>
          RAS
         </em>
         mutation [
         <a href="#rid152">
          152
         </a>
         ]. Having a
         <em>
          RAS
         </em>
         mutation was a risk factor for worse overall survival (hazard ratio [HR] 1.67, p = 0.0031) and disease-free survival (HR 1.70, p = 0.0024).
        </p>
        <p>
         While
         <em>
          RAS
         </em>
         mutations have generally been associated with more aggressive tumor biology and hence worse survival [
         <a href="#rid153">
          153
         </a>
         ], their prognostic significance appears to differ by the specific site of metastases. In one study of 193 patients who underwent CRLM resection after chemotherapy,
         <em>
          RAS
         </em>
         mutations were associated with early lung but not liver recurrence [
         <a href="#rid153">
          153
         </a>
         ]. In another study, 720 patients underwent resection of liver, lung, or peritoneal colorectal metastases. Patients whose tumors contained a
         <em>
          RAS
         </em>
         mutation had significantly worse OS after resection of liver, but not lung or peritoneal, metastases [
         <a href="#rid154">
          154
         </a>
         ].
        </p>
        <p>
         Finally, the impact of
         <em>
          RAS
         </em>
         mutations may also differ by the specific mutation within the
         <em>
          RAS
         </em>
         gene. A study evaluating
         <em>
          KRAS
         </em>
         and
         <em>
          NRAS
         </em>
         mutations in 165 patients undergoing resection of CRLMs found that exon 4 mutations were associated with large, solitary metastases occurring after long disease-free intervals, while exon 3 mutations presented with small, numerous lesions [
         <a href="#rid155">
          155
         </a>
         ]. Furthermore, patients with exon 4 mutations recurred infrequently and had longer OS compared to those with wild-type
         <em>
          RAS
         </em>
         or other
         <em>
          RAS
         </em>
         mutations (eg, in exon 2).
        </p>
        <p>
         The implications of
         <em>
          RAS
         </em>
         mutations on treatment of colorectal cancer are further discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2484.html" rel="external">
          "Pathology and prognostic determinants of colorectal cancer", section on 'RAS and BRAF'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'RAS'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1566846393">
         <span class="h3">
          BRAF mutation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mutations in the
         <em>
          BRAF
         </em>
         gene have also been linked to poor prognosis after resection of CRLMs [
         <a href="#rid156">
          156-158
         </a>
         ].
         <em>
          BRAF
         </em>
         mutations affect the same signaling pathway as
         <em>
          RAS
         </em>
         mutations, with
         <em>
          BRAF
         </em>
         acting downstream from
         <em>
          RAS
         </em>
         . The incidence of
         <em>
          BRAF
         </em>
         mutations in resected CRLMs is lower than that of
         <em>
          RAS
         </em>
         mutations (2 to 4 percent versus 30 to 40 percent). Most mutations of
         <em>
          BRAF
         </em>
         occur in codon 600 (V600E). (See
         <a class="medical medical_review" href="/z/d/html/2484.html" rel="external">
          "Pathology and prognostic determinants of colorectal cancer", section on 'RAS and BRAF'
         </a>
         .)
        </p>
        <p>
         In a multicenter retrospective study of 853 patients undergoing hepatectomy for CRLM, 5, 38, and 57 percent had a mutation in
         <em>
          BRAF
         </em>
         ,
         <em>
          RAS
         </em>
         , and neither gene, respectively [
         <a href="#rid159">
          159
         </a>
         ]. A V600E mutation, but not non-V600E mutations of
         <em>
          BRAF
         </em>
         , is associated with worse overall survival (HR 2.76, 95% CI 1.74-4.37) and disease-free survival (HR 2.04, 95% CI 1.3-3.2). The V600E
         <em>
          BRAF
         </em>
         mutation was more strongly associated with overall and disease-free survivals than
         <em>
          RAS
         </em>
         mutations.
        </p>
        <p>
         In another large multi-institutional study, 1497 patients with known
         <em>
          BRAF
         </em>
         mutation status underwent hepatectomy for CRLM [
         <a href="#rid160">
          160
         </a>
         ], of whom 2 percent had a
         <em>
          BRAF
         </em>
         mutation (71 percent of which were specifically V600E). Having a
         <em>
          BRAF
         </em>
         mutation was associated with poorer overall (median 40 versus 81 months, p &lt;0.001) and recurrence-free (median 10 versus 22 months, p &lt;0.001) survival. Despite the poor prognosis, patients with
         <em>
          BRAF
         </em>
         -mutated tumors who had node-negative primary tumors, a carcinoembryonic antigen (CEA) level &lt;200 mg/L, and clinical risk score (CRS) &lt;4 were able to achieve long-term survival.
        </p>
        <p>
         These data show that only a small percentage of patients with potentially
         <strong>
          resectable
         </strong>
         colorectal liver metastases present with a
         <em>
          BRAF
         </em>
         mutation. Even though prognosis is poor in this group, some patients are able to achieve long-term survival and may be cured using this approach. Therefore, it is difficult to justify denying a patient an attempted resection based solely on
         <em>
          BRAF
         </em>
         mutation status. However, that information can be used to help counsel the patient about the likelihood of recurrence and may dissuade surgery if the risks from a resection exceed the benefit when taking into account tumor biology based upon mutation status.
        </p>
        <p class="headingAnchor" id="H3256610472">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115274.html" rel="external">
          "Society guideline links: Colorectal cancer"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/127358.html" rel="external">
          "Society guideline links: Colorectal surgery for cancer"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/116782.html" rel="external">
          "Society guideline links: Liver resection and ablation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3334242299">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatic resection is the only curative option for patients with colorectal liver metastases (CRLMs). Survival after resection has doubled, reaching almost 60 percent in the modern era. Perioperative mortality is typically &lt;5 percent, and it is &lt;1 percent in high-volume centers. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Perioperative'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Operative planning should be based on maintaining inflow (hepatic artery and portal vein), outflow (hepatic veins), biliary drainage, and adequate future liver reserve to prevent post-hepatectomy liver failure. Anatomically speaking, if an R0 resection can be accomplished and a functional residual liver volume preserved, other negative prognostic factors should not preclude surgery. However, patient-related factors (eg, comorbidities) can prohibit surgery. (See
         <a class="local">
          'Patient selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Either high-quality computed tomography (CT) or magnetic resonance imaging (MRI) can be used to determine the quantity and location of CRLMs and their resectability. The quality of the liver should also be assessed as preoperative chemotherapy can cause liver injury. In general, a healthy liver requires a future liver remnant volume of &gt;20 percent, and &gt;30 percent is needed for livers that have undergone chemotherapy-associated changes. (See
         <a class="local">
          'Preoperative evaluation'
         </a>
         above and
         <a class="local">
          'Chemotherapy-related liver toxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical risk scores can be used to counsel patients by determining the risk of recurrence and overall survival. Response to neoadjuvant chemotherapy is one of the strongest predictors of long-term survival and recurrence. Morphologic changes in response to chemotherapy rather than size can provide prognostic data. (See
         <a class="local">
          'Tumor factors'
         </a>
         above and
         <a class="local">
          'Morphologic response'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CRLMs smaller than 2 cm and &gt;1 cm deep in the liver are at greatest risk of disappearing (radiographically) after systemic chemotherapy. They should still be resected because complete pathologic response is rare. Fiducial placement prior to systemic therapy can facilitate identification of these lesions at the time of resection. (See
         <a class="local">
          'Fiducial placement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Synchronous CRLMs can be resected using simultaneous, classic (colorectal-first), or reverse (liver-first) approaches. The timing and sequence of resections mostly depend on the acuity of symptoms and disease burden (see
         <a class="local">
          'Synchronous colorectal liver metastases'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients who present with symptoms from the primary colorectal cancer (CRC), such as bleeding, obstruction, or perforation, should undergo resection of the colorectal primary tumor first. Following postoperative recovery and two to three months of systemic chemotherapy, resection of the CRLMs is performed if there is no disease progression. (See
         <a class="local">
          'Classic (colorectal-first) approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with extensive bilobar diseases would benefit from the classic (colorectal-first), two-staged approach: at the time of colorectal primary resection, some CRLMs are resected with partial hepatectomies, leaving tumors behind on the portion of the liver that will be treated with a future anatomic resection. The patient then undergoes embolization of the portal vein on the side with the remaining tumors. After an adequate increase in the future liver remnant, a formal anatomic resection of the remaining diseases can be performed at the second-stage operation  (
         <a class="graphic graphic_figure graphicRef116621" href="/z/d/graphic/116621.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with a colorectal primary lesion in a favorable location (eg, right colon) and limited liver metastases may undergo simultaneous resection. Simultaneous resection should be used cautiously when both the liver and colorectal tumors require an extensive resection. When simultaneous resection is performed, the liver resection is performed first. If the hepatic resection is more extensive than anticipated, or there is greater blood loss than anticipated, and/or the patient is not tolerating the procedure, the colorectal portion should be postponed and a staged approach utilized. (See
         <a class="local">
          'Simultaneous resection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Parenchymal-sparing resections achieve similar oncologic outcomes to those of anatomic resections while preserving greater hepatic reserve, which potentially increases salvageability in case of hepatic recurrence. While still debated, current trends are moving toward nonanatomic parenchymal-sparing resections for CRLMs. (See
         <a class="local">
          'Parenchymal-sparing versus anatomic resection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The goal of CRLM resection should be to obtain negative margins. When anatomically feasible, we suggest obtaining resection margins of &gt;10 mm (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). However, resection should still be offered if a minimal margin of &gt;1 mm can be achieved. Every effort should be made to achieve a negative initial margin as intraoperative reresection of the margin based on frozen section results has not been associated with the same survival advantage as the initial margin. (See
         <a class="local">
          'Wide versus narrow margin'
         </a>
         above and
         <a class="local">
          'Intraoperative reresection to obtain negative margins'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Special consideration should be given to patients with
         <em>
          RAS
         </em>
         -mutated and
         <em>
          BRAF
         </em>
         -mutated (V600E) tumors as they have poorer survival and more positive margins when using standard surgical techniques. Wider negative margins (eg, &gt;1 cm) and/or anatomic resection may benefit this population, although narrow margins are likely reflective of aggressive tumor biology rather than poor technique. (See
         <a class="local">
          'RAS mutational status'
         </a>
         above and
         <a class="local">
          'RAS mutation'
         </a>
         above and
         <a class="local">
          'BRAF mutation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We routinely perform an air cholangiogram after anatomic or multiple nonanatomic liver resections to minimize the risk of bile leak. We do not routinely place abdominal drains intraoperatively. (See
         <a class="local">
          'Air cholangiogram'
         </a>
         above and
         <a class="local">
          'Drains'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CRLM recurrence after resection is common, and reresection is a safe and feasible option in properly selected patients with adequate future liver reserve and good performance status. (See
         <a class="local">
          'Repeat resection for colorectal liver metastases'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loree JM, Kopetz S. Why a One Size Fits All Approach to RAS Might Not Fit Colorectal Cancer. J Natl Compr Canc Netw 2017; 15:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 1996; 77:1254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagashima I, Takada T, Adachi M, et al. Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors. World J Gastroenterol 2006; 12:6305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konopke R, Kersting S, Distler M, et al. Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int 2009; 29:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wimmer K, Schwarz C, Szabo C, et al. Impact of Neoadjuvant Chemotherapy on Clinical Risk Scores and Survival in Patients with Colorectal Liver Metastases. Ann Surg Oncol 2017; 24:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts KJ, White A, Cockbain A, et al. Performance of prognostic scores in predicting long-term outcome following resection of colorectal liver metastases. Br J Surg 2014; 101:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamashita S, Brudvik KW, Kopetz SE, et al. Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases. Ann Surg 2018; 267:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berri RN, Abdalla EK. Curable metastatic colorectal cancer: recommended paradigms. Curr Oncol Rep 2009; 11:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charnsangavej C, Clary B, Fong Y, et al. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006; 13:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adam R, de Haas RJ, Wicherts DA, et al. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J Clin Oncol 2008; 26:3672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaeck D, Nakano H, Bachellier P, et al. Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study. Ann Surg Oncol 2002; 9:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nordlinger B, Vaillant JC, Guiguet M, et al. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 1994; 12:1491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008; 13:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pulitanò C, Bodingbauer M, Aldrighetti L, et al. Colorectal liver metastasis in the setting of lymph node metastasis: defining the benefit of surgical resection. Ann Surg Oncol 2012; 19:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bipat S, van Leeuwen MS, Comans EF, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis. Radiology 2005; 237:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamel IR, Choti MA, Horton KM, et al. Surgically staged focal liver lesions: accuracy and reproducibility of dual-phase helical CT for detection and characterization. Radiology 2003; 227:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Floriani I, Torri V, Rulli E, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 2010; 31:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Görgec B, Hansen IS, Kemmerich G, et al. MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial. Lancet Oncol 2024; 25:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulemann V, Schima W, Tamandl D, et al. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur J Radiol 2011; 79:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scharitzer M, Ba-Ssalamah A, Ringl H, et al. Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. Eur Radiol 2013; 23:2187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahani DV, Bajwa MA, Andrabi Y, et al. Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma. Ann Surg 2014; 259:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moulton CA, Gu CS, Law CH, et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA 2014; 311:1863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiering B, Krabbe PF, Jager GJ, et al. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005; 104:2658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pawlik TM, Assumpcao L, Vossen JA, et al. Trends in nontherapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases. Ann Surg Oncol 2009; 16:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruers TJ, Wiering B, van der Sijp JR, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med 2009; 50:1036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruers TJ, Langenhoff BS, Neeleman N, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002; 20:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fong Y, Saldinger PF, Akhurst T, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999; 178:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai DT, Fulham M, Stephen MS, et al. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996; 131:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valk PE, Abella-Columna E, Haseman MK, et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999; 134:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imdahl A, Reinhardt MJ, Nitzsche EU, et al. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg 2000; 385:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langenhoff BS, Oyen WJ, Jager GJ, et al. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002; 20:4453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akhurst T, Kates TJ, Mazumdar M, et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 2005; 23:8713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glazer ES, Beaty K, Abdalla EK, et al. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg 2010; 145:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Kessel CS, Buckens CF, van den Bosch MA, et al. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol 2012; 19:2805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grothey A, Hedrick EE, Mass RD, et al. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 2008; 26:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shindoh J, Loyer EM, Kopetz S, et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 2012; 30:4566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008; 26:2717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302:2338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24:3939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auer RC, White RR, Kemeny NE, et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010; 116:1502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Vledder MG, de Jong MC, Pawlik TM, et al. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg 2010; 14:1691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elias D, Goere D, Boige V, et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007; 14:3188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Passot G, Odisio BC, Zorzi D, et al. Eradication of Missing Liver Metastases After Fiducial Placement. J Gastrointest Surg 2016; 20:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zalinski S, Abdalla EK, Mahvash A, Vauthey JN. A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy. Ann Surg Oncol 2009; 16:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mekenkamp LJ, Koopman M, Teerenstra S, et al. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer 2010; 103:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adam R, Laurent A, Azoulay D, et al. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 2000; 232:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaeck D, Oussoultzoglou E, Rosso E, et al. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 2004; 240:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsai S, Marques HP, de Jong MC, et al. Two-stage strategy for patients with extensive bilateral colorectal liver metastases. HPB (Oxford) 2010; 12:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lykoudis PM, O'Reilly D, Nastos K, Fusai G. Systematic review of surgical management of synchronous colorectal liver metastases. Br J Surg 2014; 101:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feng Q, Wei Y, Zhu D, et al. Timing of hepatectomy for resectable synchronous colorectal liver metastases: for whom simultaneous resection is more suitable--a meta-analysis. PLoS One 2014; 9:e104348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veereman G, Robays J, Verleye L, et al. Pooled analysis of the surgical treatment for colorectal cancer liver metastases. Crit Rev Oncol Hematol 2015; 94:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boudjema K, Locher C, Sabbagh C, et al. Simultaneous Versus Delayed Resection for Initially Resectable Synchronous Colorectal Cancer Liver Metastases: A Prospective, Open-label, Randomized, Controlled Trial. Ann Surg 2021; 273:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silberhumer GR, Paty PB, Temple LK, et al. Simultaneous resection for rectal cancer with synchronous liver metastasis is a safe procedure. Am J Surg 2015; 209:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Driedger MR, Yamashita TS, Starlinger P, et al. Synchronous resection of colorectal cancer primary and liver metastases: an outcomes analysis. HPB (Oxford) 2021; 23:1277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCahill LE, Yothers G, Sharif S, et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J Clin Oncol 2012; 30:3223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009; 27:3379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang SB, Palavecino M, Wray CJ, et al. Modified Makuuchi incision for foregut procedures. Arch Surg 2010; 145:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 2003; 197:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyass S, Zamir G, Matot I, et al. Combined colon and hepatic resection for synchronous colorectal liver metastases. J Surg Oncol 2001; 78:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin RC 2nd, Augenstein V, Reuter NP, et al. Simultaneous versus staged resection for synchronous colorectal cancer liver metastases. J Am Coll Surg 2009; 208:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy SK, Pawlik TM, Zorzi D, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol 2007; 14:3481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlag P, Hohenberger P, Herfarth C. Resection of liver metastases in colorectal cancer--competitive analysis of treatment results in synchronous versus metachronous metastases. Eur J Surg Oncol 1990; 16:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkins LT, Millikan KW, Bines SD, et al. Hepatic resection for metastatic colorectal cancer. Am Surg 1997; 63:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen PJ, Kemeny N, Jarnagin W, et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003; 7:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slesser AA, Simillis C, Goldin R, et al. A meta-analysis comparing simultaneous versus delayed resections in patients with synchronous colorectal liver metastases. Surg Oncol 2013; 22:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mentha G, Majno PE, Andres A, et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006; 93:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam VW, Laurence JM, Pang T, et al. A systematic review of a liver-first approach in patients with colorectal cancer and synchronous colorectal liver metastases. HPB (Oxford) 2014; 16:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly ME, Spolverato G, Lê GN, et al. Synchronous colorectal liver metastasis: a network meta-analysis review comparing classical, combined, and liver-first surgical strategies. J Surg Oncol 2015; 111:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarpel U, Bonavia AS, Grucela A, et al. Does anatomic versus nonanatomic resection affect recurrence and survival in patients undergoing surgery for colorectal liver metastasis? Ann Surg Oncol 2009; 16:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moris D, Ronnekleiv-Kelly S, Rahnemai-Azar AA, et al. Parenchymal-Sparing Versus Anatomic Liver Resection for Colorectal Liver Metastases: a Systematic Review. J Gastrointest Surg 2017; 21:1076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deng G, Li H, Jia GQ, et al. Parenchymal-sparing versus extended hepatectomy for colorectal liver metastases: A systematic review and meta-analysis. Cancer Med 2019; 8:6165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mise Y, Aloia TA, Brudvik KW, et al. Parenchymal-sparing Hepatectomy in Colorectal Liver Metastasis Improves Salvageability and Survival. Ann Surg 2016; 263:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andreou A, Aloia TA, Brouquet A, et al. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 2013; 257:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cady B, Jenkins RL, Steele GD Jr, et al. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 1998; 227:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ekberg H, Tranberg KG, Andersson R, et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986; 73:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viganò L, Capussotti L, Lapointe R, et al. Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6,025 patients. Ann Surg Oncol 2014; 21:1276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qadan M, D'Angelica MI. Extending the Limits of Resection for Colorectal Liver Metastases: Positive Resection Margin and Outcome After Resection of Colorectal Cancer Liver Metastases. J Gastrointest Surg 2017; 21:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Margonis GA, Sergentanis TN, Ntanasis-Stathopoulos I, et al. Impact of Surgical Margin Width on Recurrence and Overall Survival Following R0 Hepatic Resection of Colorectal Metastases: A Systematic Review and Meta-analysis. Ann Surg 2018; 267:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadot E, Groot Koerkamp B, Leal JN, et al. Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? Ann Surg 2015; 262:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller CL, Taylor MS, Qadan M, et al. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. J Gastrointest Surg 2017; 21:1831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Margonis GA, Amini N, et al. The Prognostic Value of Varying Definitions of Positive Resection Margin in Patients with Colorectal Cancer Liver Metastases. J Gastrointest Surg 2018; 22:1350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kokudo N, Miki Y, Sugai S, et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg 2002; 137:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holdhoff M, Schmidt K, Diehl F, et al. Detection of tumor DNA at the margins of colorectal cancer liver metastasis. Clin Cancer Res 2011; 17:3551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brudvik KW, Mise Y, Chung MH, et al. RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. Ann Surg Oncol 2016; 23:2635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Margonis GA, Sasaki K, Andreatos N, et al. KRAS Mutation Status Dictates Optimal Surgical Margin Width in Patients Undergoing Resection of Colorectal Liver Metastases. Ann Surg Oncol 2017; 24:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Margonis GA, Buettner S, Andreatos N, et al. Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases. Ann Surg 2017; 266:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wray CJ, Lowy AM, Matthews JB, et al. Intraoperative margin re-resection for colorectal liver metastases. J Surg Educ 2007; 64:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Margonis GA, Spolverato G, Kim Y, et al. Intraoperative surgical margin re-resection for colorectal liver metastasis: is it worth the effort? J Gastrointest Surg 2015; 19:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimmitti G, Vauthey JN, Shindoh J, et al. Systematic use of an intraoperative air leak test at the time of major liver resection reduces the rate of postoperative biliary complications. J Am Coll Surg 2013; 217:1028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burt BM, Brown K, Jarnagin W, et al. An audit of results of a no-drainage practice policy after hepatectomy. Am J Surg 2002; 184:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fong Y, Brennan MF, Brown K, et al. Drainage is unnecessary after elective liver resection. Am J Surg 1996; 171:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Squires MH 3rd, Lad NL, Fisher SB, et al. Value of primary operative drain placement after major hepatectomy: a multi-institutional analysis of 1,041 patients. J Am Coll Surg 2015; 220:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratti F, Fiorentini G, Cipriani F, et al. Laparoscopic vs Open Surgery for Colorectal Liver Metastases. JAMA Surg 2018; 153:1028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Syn NL, Kabir T, Koh YX, et al. Survival Advantage of Laparoscopic Versus Open Resection For Colorectal Liver Metastases: A Meta-analysis of Individual Patient Data From Randomized Trials and Propensity-score Matched Studies. Ann Surg 2020; 272:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garden OJ, Rees M, Poston GJ, et al. Guidelines for resection of colorectal cancer liver metastases. Gut 2006; 55 Suppl 3:iii1.
          </a>
         </li>
         <li class="breakAll">
          Petrelli NJ. Plenary program discussion. 43rd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4, 2007.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009; 27:1829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23:9243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delaunoit T, Alberts SR, Sargent DJ, et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 2005; 16:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barone C, Nuzzo G, Cassano A, et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 2007; 97:1035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ychou M, Viret F, Kramar A, et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 2008; 62:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009; 249:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25:1670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wein A, Riedel C, Köckerling F, et al. Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol 2001; 12:1721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evrard S, Poston G, Kissmeyer-Nielsen P, et al. Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases. PLoS One 2014; 9:e114404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbott DE, Sohn VY, Hanseman D, Curley SA. Cost-effectiveness of simultaneous resection and RFA versus 2-stage hepatectomy for bilobar colorectal liver metastases. J Surg Oncol 2014; 109:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009; 250:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006; 94:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Trigo V, Shamsa F, Sugarbaker PH. Repeat liver resections from colorectal metastasis. Repeat Hepatic Metastases Registry. Surgery 1995; 117:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adam R, Bismuth H, Castaing D, et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997; 225:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto J, Kosuge T, Shimada K, et al. Repeat liver resection for recurrent colorectal liver metastases. Am J Surg 1999; 178:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petrowsky H, Gonen M, Jarnagin W, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002; 235:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagakura S, Shirai Y, Suda T, Hatakeyama K. Multiple repeat resections of intra- and extrahepatic recurrences in patients undergoing initial hepatectomy for colorectal carcinoma metastases. World J Surg 2002; 26:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka K, Shimada H, Ohta M, et al. Procedures of choice for resection of primary and recurrent liver metastases from colorectal cancer. World J Surg 2004; 28:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pessaux P, Lermite E, Brehant O, et al. Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol 2006; 93:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishiguro S, Akasu T, Fujimoto Y, et al. Second hepatectomy for recurrent colorectal liver metastasis: analysis of preoperative prognostic factors. Ann Surg Oncol 2006; 13:1579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan TD, Sim J, Black D, et al. Systematic review on safety and efficacy of repeat hepatectomy for recurrent liver metastases from colorectal carcinoma. Ann Surg Oncol 2007; 14:2069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sa Cunha A, Laurent C, Rault A, et al. A second liver resection due to recurrent colorectal liver metastases. Arch Surg 2007; 142:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones NB, McNally ME, Malhotra L, et al. Repeat hepatectomy for metastatic colorectal cancer is safe but marginally effective. Ann Surg Oncol 2012; 19:2224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adair RA, Young AL, Cockbain AJ, et al. Repeat hepatic resection for colorectal liver metastases. Br J Surg 2012; 99:1278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wicherts DA, de Haas RJ, Salloum C, et al. Repeat hepatectomy for recurrent colorectal metastases. Br J Surg 2013; 100:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butte JM, Gönen M, Allen PJ, et al. Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection. Ann Surg Oncol 2015; 22:2761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gomez D, Sangha VK, Morris-Stiff G, et al. Outcomes of intensive surveillance after resection of hepatic colorectal metastases. Br J Surg 2010; 97:1552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodingbauer M, Tamandl D, Schmid K, et al. Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. Br J Surg 2007; 94:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Haas RJ, Wicherts DA, Flores E, et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 2008; 248:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andreou A, Brouquet A, Abdalla EK, et al. Repeat hepatectomy for recurrent colorectal liver metastases is associated with a high survival rate. HPB (Oxford) 2011; 13:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neal CP, Nana GR, Jones M, et al. Repeat hepatectomy is independently associated with favorable long-term outcome in patients with colorectal liver metastases. Cancer Med 2017; 6:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imai K, Benitez CC, Allard MA, et al. Impact of Surgical Treatment for Recurrence After 2-Stage Hepatectomy for Colorectal Liver Metastases, on Patient Outcome. Ann Surg 2019; 269:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lillemoe HA, Kawaguchi Y, Passot G, et al. Surgical Resection for Recurrence After Two-Stage Hepatectomy for Colorectal Liver Metastases Is Feasible, Is Safe, and Improves Survival. J Gastrointest Surg 2019; 23:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fahy BN, Fischer CP. Synchronous resection of colorectal primary and hepatic metastasis. J Gastrointest Oncol 2012; 3:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorcaratto D, Mazzinari G, Fernandez M, et al. Impact of Postoperative Complications on Survival and Recurrence After Resection of Colorectal Liver Metastases: Systematic Review and Meta-analysis. Ann Surg 2019; 270:1018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrarotto R, Pathak P, Maru D, et al. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer 2011; 10:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986; 100:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adson MA, Van Heerden JA. Major hepatic resections for metastatic colorectal cancer. Ann Surg 1980; 191:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steele G Jr, Bleday R, Mayer RJ, et al. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol 1991; 9:1105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon SS, Tanabe KK. Multidisciplinary management of metastatic colorectal cancer. Surg Oncol 1998; 7:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jamison RL, Donohue JH, Nagorney DM, et al. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997; 132:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999; 189:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei AC, Greig PD, Grant D, et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006; 13:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 2007; 109:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008; 247:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris EJ, Forman D, Thomas JD, et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 2010; 97:1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amikura K, Akagi K, Ogura T, et al. The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS. J Surg Oncol 2018; 117:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013; 258:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Passot G, Kim BJ, Glehen O, et al. Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter? Ann Surg Oncol 2018; 25:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frankel TL, Vakiani E, Nathan H, et al. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. Cancer 2017; 123:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Passiglia F, Bronte G, Bazan V, et al. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. Crit Rev Oncol Hematol 2016; 99:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schirripa M, Bergamo F, Cremolini C, et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer 2015; 112:1921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Umeda Y, Nagasaka T, Mori Y, et al. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. J Hepatobiliary Pancreat Sci 2013; 20:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Margonis GA, Buettner S, Andreatos N, et al. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. JAMA Surg 2018; 153:e180996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gagnière J, Dupré A, Gholami SS, et al. Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients. Ann Surg 2020; 271:147.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 115954 Version 11.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36633525" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cancer statistics, 2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28404763" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Why a One Size Fits All Approach to RAS Might Not Fit Colorectal Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10493478" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8608500" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17072953" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18673436" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27730370" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Impact of Neoadjuvant Chemotherapy on Clinical Risk Scores and Survival in Patients with Colorectal Liver Metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24817653" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Performance of prognostic scores in predicting long-term outcome following resection of colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28002060" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19336012" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Curable metastatic colorectal cancer: recommended paradigms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16947009" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Selection of patients for resection of hepatic colorectal metastases: expert consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18669451" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12052752" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8021741" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18245012" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Expanding criteria for resectability of colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21743977" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Colorectal liver metastasis in the setting of lymph node metastasis: defining the benefit of surgical resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16100087" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12773679" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Surgically staged focal liver lesions: accuracy and reproducibility of dual-phase helical CT for detection and characterization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20027569" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38081200" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20392584" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23519439" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24509207" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24825641" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15319715" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16315241" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19020939" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Trends in nontherapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19525451" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11786565" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10587184" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8678767" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10323422" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10796051" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12431968" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16314631" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20404283" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22396005" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18182660" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18421054" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23150701" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18378569" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19952320" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16921046" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Complete response of colorectal liver metastases after chemotherapy: does it mean cure?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20120032" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20839072" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Disappearing colorectal liver metastases after chemotherapy: should we be concerned?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17705091" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26791387" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Eradication of Missing Liver Metastases After Fiducial Placement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19214636" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20551951" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11088072" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8857855" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15570209" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20590896" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Two-stage strategy for patients with extensive bilateral colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24652674" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Systematic review of surgical management of synchronous colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25093337" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Timing of hepatectomy for resectable synchronous colorectal liver metastases: for whom simultaneous resection is more suitable--a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25666309" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Pooled analysis of the surgical treatment for colorectal cancer liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32209911" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Simultaneous Versus Delayed Resection for Initially Resectable Synchronous Colorectal Cancer Liver Metastases: A Prospective, Open-label, Randomized, Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25601556" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Simultaneous resection for rectal cancer with synchronous liver metastasis is a safe procedure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33541806" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Synchronous resection of colorectal cancer primary and liver metastases: an outcomes analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22869888" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19487380" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20231630" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Modified Makuuchi incision for foregut procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12892803" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11519063" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Combined colon and hepatic resection for synchronous colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19476847" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Simultaneous versus staged resection for synchronous colorectal cancer liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17805933" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2379594" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Resection of liver metastases in colorectal cancer--competitive analysis of treatment results in synchronous versus metachronous metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9202534" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Hepatic resection for metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12559192" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23253399" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : A meta-analysis comparing simultaneous versus delayed resections in patients with synchronous colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16671066" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23509899" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : A systematic review of a liver-first approach in patients with colorectal cancer and synchronous colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25363294" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Synchronous colorectal liver metastasis: a network meta-analysis review comparing classical, combined, and liver-first surgical strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19020941" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Does anatomic versus nonanatomic resection affect recurrence and survival in patients undergoing surgery for colorectal liver metastasis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28364212" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Parenchymal-Sparing Versus Anatomic Liver Resection for Colorectal Liver Metastases: a Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31464101" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Parenchymal-sparing versus extended hepatectomy for colorectal liver metastases: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25775068" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Parenchymal-sparing Hepatectomy in Colorectal Liver Metastasis Improves Salvageability and Survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23426338" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9563547" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3756436" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Determinants of survival in liver resection for colorectal secondaries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15849507" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24346766" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6,025 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27586189" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Extending the Limits of Resection for Colorectal Liver Metastases: Positive Resection Margin and Outcome After Resection of Colorectal Cancer Liver Metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29189379" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Impact of Surgical Margin Width on Recurrence and Overall Survival Following R0 Hepatic Resection of Colorectal Metastases: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26258316" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28884391" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29633114" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : The Prognostic Value of Varying Definitions of Positive Resection Margin in Patients with Colorectal Cancer Liver Metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12093342" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21531819" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Detection of tumor DNA at the margins of colorectal cancer liver metastasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27016292" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27696170" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : KRAS Mutation Status Dictates Optimal Surgical Margin Width in Patients Undergoing Resection of Colorectal Liver Metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28657938" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17574176" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Intraoperative margin re-resection for colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25451734" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Intraoperative surgical margin re-resection for colorectal liver metastasis: is it worth the effort?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24246619" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Systematic use of an intraoperative air leak test at the time of major liver resection reduces the rate of postoperative biliary complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12433610" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : An audit of results of a no-drainage practice policy after hepatectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8554132" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Drainage is unnecessary after elective liver resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25724607" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Value of primary operative drain placement after major hepatectomy: a multi-institutional analysis of 1,041 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30027220" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Laparoscopic vs Open Surgery for Colorectal Liver Metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32675538" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Survival Advantage of Laparoscopic Versus Open Resection For Colorectal Liver Metastases: A Meta-analysis of Individual Patient Data From Randomized Trials and Propensity-score Matched Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16835351" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Guidelines for resection of colorectal cancer liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16835351" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Guidelines for resection of colorectal cancer liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19273699" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16230673" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15677624" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17895897" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17901955" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19247029" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17470860" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11843250" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25485541" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24374772" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Cost-effectiveness of simultaneous resection and RFA versus 2-stage hepatectomy for bilobar colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19730175" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16538219" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7878536" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Repeat liver resections from colorectal metastasis. Repeat Hepatic Metastases Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8998120" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Repeat hepatectomy for colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10587183" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Repeat liver resection for recurrent colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12035044" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11865339" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Multiple repeat resections of intra- and extrahepatic recurrences in patients undergoing initial hepatectomy for colorectal carcinoma metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15085394" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Procedures of choice for resection of primary and recurrent liver metastases from colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16353192" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Repeat hepatectomy for recurrent colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17003958" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Second hepatectomy for recurrent colorectal liver metastasis: analysis of preoperative prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17440785" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Systematic review on safety and efficacy of repeat hepatectomy for recurrent liver metastases from colorectal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18086980" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : A second liver resection due to recurrent colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22207046" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Repeat hepatectomy for metastatic colorectal cancer is safe but marginally effective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22864889" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Repeat hepatic resection for colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23494765" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Repeat hepatectomy for recurrent colorectal metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25572686" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20632325" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Outcomes of intensive surveillance after resection of hepatic colorectal metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17514637" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18936576" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21999590" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Repeat hepatectomy for recurrent colorectal liver metastases is associated with a high survival rate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28101946" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Repeat hepatectomy is independently associated with favorable long-term outcome in patients with colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28820745" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Impact of Surgical Treatment for Recurrence After 2-Stage Hepatectomy for Colorectal Liver Metastases, on Patient Outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30084064" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Surgical Resection for Recurrence After Two-Stage Hepatectomy for Colorectal Liver Metastases Is Feasible, Is Safe, and Improves Survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22811869" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Synchronous resection of colorectal primary and hepatic metastasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30829704" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Impact of Postoperative Complications on Survival and Recurrence After Resection of Colorectal Liver Metastases: Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21855039" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3526605" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15166961" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15922194" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7369821" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Major hepatic resections for metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7740812" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Resection of colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2045852" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10677170" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Multidisciplinary management of metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9161393" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Hepatic resection for metastatic colorectal cancer results in cure for some patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10472930" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16523369" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Survival after hepatic resection for colorectal metastases: a 10-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17238180" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Survival after hepatic resection in metastatic colorectal cancer: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18156932" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20632280" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Surgical management and outcomes of colorectal cancer liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29194647" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24018645" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29071660" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27737491" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26775732" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25942399" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23010994" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29799910" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29995686" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
